Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial.
Preiss D, Thomas LE, Sun JL, Haffner SM, Holman RR, Standl E, Leiter LA, Mazzone T, Rutten GE, Tognoni G, Martinez FA, Chiang FT, Califf RM, McMurray JJ. Preiss D, et al. Among authors: standl e. BMJ Open. 2012 Nov 30;2(6):e001925. doi: 10.1136/bmjopen-2012-001925. Print 2012. BMJ Open. 2012. PMID: 23204139 Free PMC article.
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Preiss D, Giles TD, Thomas LE, Sun JL, Haffner SM, Holman RR, Standl E, Mazzone T, Rutten GE, Tognoni G, Chiang FT, McMurray JJ, Califf RM. Preiss D, et al. Among authors: standl e. Stroke. 2013 Sep;44(9):2590-3. doi: 10.1161/STROKEAHA.113.001177. Epub 2013 Jul 30. Stroke. 2013. PMID: 23899915
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
Wong YW, Thomas L, Sun JL, McMurray JJ, Krum H, Hernandez AF, Rutten GE, Leiter LA, Standl E, Haffner SM, Mazzone T, Martinez FA, Tognoni G, Giles T, Califf RM. Wong YW, et al. Among authors: standl e. Circ Heart Fail. 2013 Mar;6(2):203-10. doi: 10.1161/CIRCHEARTFAILURE.112.000086. Epub 2013 Feb 6. Circ Heart Fail. 2013. PMID: 23388113 Clinical Trial.
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
Latini R, Staszewsky L, Sun JL, Bethel MA, Disertori M, Haffner SM, Holman RR, Chang F, Giles TD, Maggioni AP, Rutten GE, Standl E, Thomas L, Tognoni G, Califf RM, McMurray JJ. Latini R, et al. Among authors: standl e. Am Heart J. 2013 Nov;166(5):935-40.e1. doi: 10.1016/j.ahj.2013.08.012. Epub 2013 Oct 7. Am Heart J. 2013. PMID: 24176451 Clinical Trial.
Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA, Engel SS, Green JB, Huang Z, Josse RG, Kaufman KD, Standl E, Suryawanshi S, Van de Werf F, McGuire DK, Peterson ED, Holman RR; TECOS Study Group. Bethel MA, et al. Among authors: standl e. Diabetes Care. 2017 Apr;40(4):494-501. doi: 10.2337/dc16-1135. Epub 2017 Jan 5. Diabetes Care. 2017. PMID: 28057693 Clinical Trial.
Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial.
McAlister FA, Zheng Y, Westerhout CM, Buse JB, Standl E, McGuire DK, Van de Werf F, Green JB, Armstrong PW, Holman RR; TECOS Study Group. McAlister FA, et al. Among authors: standl e. Eur J Heart Fail. 2020 Nov;22(11):2026-2034. doi: 10.1002/ejhf.1958. Epub 2020 Jul 28. Eur J Heart Fail. 2020. PMID: 32621557 Free article. Clinical Trial.
Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin.
Navar AM, Gallup DS, Lokhnygina Y, Green JB, McGuire DK, Armstrong PW, Buse JB, Engel SS, Lachin JM, Standl E, Van de Werf F, Holman RR, Peterson ED; TECOS Study Group. Navar AM, et al. Among authors: standl e. Hypertension. 2017 Nov;70(5):907-914. doi: 10.1161/HYPERTENSIONAHA.117.09482. Epub 2017 Aug 28. Hypertension. 2017. PMID: 28847886 Free PMC article. Clinical Trial.
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED; Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group. McGuire DK, et al. Among authors: standl e. JAMA Cardiol. 2016 May 1;1(2):126-35. doi: 10.1001/jamacardio.2016.0103. JAMA Cardiol. 2016. PMID: 27437883 Clinical Trial.
303 results